Gryphon Bio is an early-stage company created to harness our co-founders' discovery of unexpected waves of 1000s of brain molecules in the blood as novel therapeutic targets and temporal blood biomarkers (brain-specific proteins with blood levels that change over time like waves in the ocean). They made these discoveries over more than 20 years of “brain proteomic” research, the large-scale measurement of proteins in the brain.
Mission: To develop and market the first diagnostic-powered therapeutics for brain health.
Vision: To pioneer diagnostic-powered therapeutics to improve the lives of patients.
Company Details
- Employees
- 7
- Founded
- 2018
- Address
- 611 Gateway Blvd,
- bd****@****bio.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gryphonbio.com
- Keywords
- traumatic brain injury, multiple sclerosis, epilepsy, Alzheimer's disease, chronic traumatic encephalopathy, temporal biomarkers, brain medicine, therapeutic bioconjugate, antibody.
- HQ
- South San Francisco, California
Gryphon Bio Questions
Gryphon Bio's website is gryphonbio.com
Gryphon Bio's LinkedIn profile is https://www.linkedin.com/company/gryphon-bio
Gryphon Bio has
7 employees.
View email and phone details for 7
employees at Gryphon Bio.
Gryphon Bio's industry is
Biotechnology Research
Gryphon Bio's top competitors are
Alligator Bioscience Ab,
Owl Therapeutics,
Alx Oncology,
2stringz, Llc,
Hansa Biopharma,
Abliva Ab,
Cellevate Ab,
Arthex Biotech,
Omniab, Inc.,
Elicera Therapeutics Ab.
Gryphon Bio's support email address is bd@gryphonbio.com
Gryphon Bio's categories are Biotechnology Research
Gryphon Bio's founding year is 2018
